FDA accepts the new drug application for review of Idorsia s daridorexant for the treatment of apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.
• The application includes robust data from the Phase 3 registration program, which demonstrated efficacy of daridorexant on objective and subjective sleep parameters, and an improvement in daytime
(2)
NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Focus Financial Partners Inc. (NASDAQ:FOCS) ( Focus ), a leading partnership of independent, fiduciary wealth management firms, announced today that Rollins Financial, Inc. ( Rollins Financial ), a registered investment adviser headquartered in Atlanta, Georgia has entered into an agreement to join the Focus partnership. The transaction is expected to close in the second quarter of 2021, subject to customary closing conditions.
Founded in 1990 by Joe Rollins, Rollins Financial utilizes a comprehensive, highly client-centric service model to provide financial planning, tax planning and investment management services to high net worth clients primarily across the Southeast. When I founded Rollins Financial in 1990, the investment advisory business seemed a natural complement to my existing tax and accounting practice, said Joe Rollins, Founder and CEO of Rollins Financial, I wanted to build a firm dedicated to independent and transpa
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Idorsia submits NDA for clazosentan to Japanese PMDA
Idorsia Pharmaceuticals LtdMarch 1, 2021 GMT
Allschwil, Switzerland – March 1, 2021
Idorsia Ltd (SIX: IDIA) today announced the submission of a New Drug Application (NDA) to the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) for clazosentan, a fast-acting, selective endothelin A (ETA) receptor antagonist, for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH).
The application is supported by replicated results from the Japanese registration program which consisted of two double-blind, randomized, placebo-controlled studies assessing the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality events in adult Japanese patients following aSAH. Patients were randomized to receiv
Rollins Financial to Join Focus as a Partner Firm, Expanding Focus Presence in the Southeast apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.